Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications

Abstract

If there is a great new hope in the treatment of cancer, the immune system is it. Innate and adaptive immunity either promote or attenuate tumorigenesis and so can have opposing effects on the therapeutic outcome. Originally described as potent antivirals, Type-I interferons (IFNs) were quickly recognized as central coordinators of tumor-immune system interactions. Type-I-IFNs are produced by, and act on, both tumor and immune cells being either host-protecting or tumor-promoting. Here, we discuss Type-I-IFNs in infectious and cancer diseases highlighting their dichotomous role and raising the importance to deeply understand the underlying mechanisms so to reshape the way we can exploit Type-I-IFNs therapeutically.

Interferon status as a method of determination of nonspecific biomarkers of human immunopathology

“…Были расшифрованы молекулярные механизмы образования и действия ИФН, установлены пути передачи ИФН сигнала, его взаимосвязь с другими цитокинами, механизмами регуляции естественного иммунитета и участием в патогенезе аутоиммунных заболеваний [15, 17, 22, 24, 30-32, 35, 38, 40, 45, 50]. Именно интерфероны стали первыми перспективными источниками рекомбинантных молекул, использованных для создания лекарственных средств (ЛС) с применением современных методов нанобиотехнологии [1,5,10,11,21,36,41].…”

Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment

“…Cancer cells infected with OVs self-destruct, thereby attracting the attention of immune cells such as TILs or neutrophils leading to the production of inflammatory mediators, consequently eliminating the main tumor and potentially other tumors within the body. OVs can also induce viral infection cascades known to elicit a type 1 interferon response thereby stimulating cytokine release, cancer cell lysis, and apoptosis (97,98). The first OV approved by the FDA was Imlygic, a herpes simplex virus I tweaked to preferentially kill cancer cells, which was approved in 2015 for the treatment of advanced melanoma (39,99).…”

Immune Regulatory Network in Cervical Cancer Development: The Expanding Role of Innate Immunity Mechanisms

“…What reasons could underlie these contradictions? On one hand, the STING-induced production of type I IFNs and activation of inflammatory reactions are obviously indispensable for the proper functioning of antigen-presenting cells (APC) and for further induction of adaptive antitumor response (discussed in [13,19,20]). On the other hand, the increased activity of STING leads to chronic inflammation within the locus of neoplasia which is a driving force of immunosuppression and tumorigenesis.…”